依达拉奉辅助治疗急性期脑梗死的临床观察

Clinical Observation on Edaravone in Adjuvant Treatment of Acute Cerebral Infarction

目的:评价依达拉奉辅助治疗急性期脑梗死的疗效及安全性。方法:将114例急性脑梗死患者,随机分为治疗组(依达拉奉+常规治疗)和对照组(常规治疗),对两组患者治疗前及治疗后第7、14天超敏C-反应蛋白(hs-CRP)、神经功能缺损评分和临床疗效进行比较。结果:治疗后第7、14天,两组hs-CRP均明显下降,治疗组比对照组下降更明显;神经功能缺损评分、临床疗效的总有效率,治疗组较对照组改善更明显,比较差异有统计学意义(P<0.05)。结论:依达拉奉辅助治疗急性脑梗死效果理想,能有效改善急性期脑梗死的神经功能缺损。

Objective： To evaluate the efficacy and safety of edaravone in treatment of acute cerebral infarction. To investigate the effect of edaravone on treatment and safety in patients with acute cerebral infarction. Methods： A total of 114 cases with acute cerebral infarction were randomly divided into edaravone treatment group and control group（accepting conventional treatment）. Serum levels of high-sensitivity C-reactive protein（hs-CRP）, european stroke scale（ESS） Grade and clinical efficacy were detected on days 7 and14 after the treatment. Results： The hs-CRP levels in the treatment group were reduced much more than control group; ESS Grade and clinical efficacy were better in the treatment group compared with the control group, and there was significant difference between the two groups（P〈0.05）. Conclusions： The edaravone can improve the neurologic impairment in patients with acute cerebral infarction.